Delayed in vivo catabolism of intermediate-density lipoprotein and low-density lipoprotein in hemodialysis patients as potential cause of premature atherosclerosis.
نویسندگان
چکیده
OBJECTIVE Premature cardiovascular disease is the leading cause of death in patients with end-stage renal disease treated by hemodialysis (HD). Low-density lipoprotein (LDL) levels are not generally increased in HD patients, but their LDL metabolism is still poorly understood. We therefore investigated the in vivo metabolism of apoB-containing lipoproteins in two different ethnic populations of HD patients and controls. METHODS AND RESULTS We performed stable isotope kinetic studies using a primed constant infusion of deuterated leucine in 12 HD patients and 13 healthy controls. Tracer/tracee ratio of apoB was determined by means of gas chromatography/mass spectrometry, and the modeling program SAAMII was used to estimate the fractional catabolic rate (FCR) of apoB. Mean LDL-apoB plasma concentrations were almost identical in both groups (HD: 95+/-30 mg/dL, controls: 91+/-40 mg/dL), whereas LDL-apoB FCR was 50% lower in HD patients as compared with controls (0.22+/-0.12 days(-1) versus 0.46+/-0.20 days(-1), P=0.001) with concomitantly decreased production rates of LDL. Compared with controls, intermediate-density lipoprotein (IDL)-apoB FCR was 65% lower (2.87+/-1.02 days(-1) versus 8.89+/-4.94 days(-1), P=0.014), accompanied by 1.5-fold higher IDL-apoB levels in HD. Very low-density lipoprotein metabolism was similar in both study groups. CONCLUSIONS In vivo catabolism of LDL and IDL is severely impaired in HD patients but misleadingly masked by normal plasma cholesterol levels. The resulting markedly prolonged residence times of both IDL and LDL particles might thus significantly contribute to the well-documented high risk for premature cardiovascular disease in HD patients.
منابع مشابه
Lipoprotein in Hemodialysis Patients as Potential Cause of Premature Atherosclerosis Delayed In Vivo Catabolism of Intermediate-Density Lipoprotein and Low-Density
Seibu Mochizuki, Benjamin Dieplinger, Evi Trenkwalder, Horst Schweer, Florian Kronenberg, Katsunori Ikewaki, Juergen R. Schaefer, Michael E. Frischmann, Keio Okubo, Tatsuo Hosoya, Lipoprotein in Hemodialysis Patients as Potential Cause of Premature Atherosclerosis Delayed In Vivo Catabolism of Intermediate-Density Lipoprotein and Low-Density Print ISSN: 1079-5642. Online ISSN: 1524-4636 Copyrig...
متن کاملComparative Effects of Copper, Iron, Vanadium and Titanium on Low Density Lipoprotein Oxidation in vitro
Oxidation of low density lipoprotein (LDL) has been strongly implicated in the phathogenesis of atherosclerosis. The use of oxidants in dietary food stuff may lead to the production of oxidized LDL and may increase both the development and the progression of atherosclerosis. The present work investigated the effects of some elements including: copper (Cu), iron (Fe), vanadium (V) and titanium (...
متن کاملRelationship between High-Density Lipoprotein and C-reactive Protein in Patients with Atherosclerosis
Abstract Background and Objective: Atherosclerosis is an inflammatory disease mostly caused by oxidation of low density lipoproteins (LDLs) while High-density lipoproteins (HDLs) oppose atherosclerosis by inhibiting the oxidation of LDLs. Serum concentration of C- reactive protein (CRP) also increases as an acute phase protein in inflammatory conditions like atherosclerosis. We aimed to evalu...
متن کاملارزیابی عوامل مؤثر در پراکسیداسیون لیپیدی بیماران همودیالیزی و پیوندی
Evaluation the Affecting Factors in Lipid Peroxidation of Hemodialysis and Renal Transplanted Patients GR. Moshtaghi Kashanian PhD , N. Rashtchi PhD , H. Ardakani MD , A. Ghorbani Haghjoo PhD2 Received: 23/07/05 Sent for Revision: 25/09/06 Received Revised Manuscript: 21/01/07 Accepted: 26/02/07 Background and Objective: Atherosclerosis is the most important cause of death in hemodial...
متن کاملEvalution of In Vitro Effect of Flavonoids on Human Low-Density Lipoprotein Carbamylation
The non-enzymatic carbamylation of low density lipoprotein (LDL) is a naturally occurring chemical modification of apolipoprotein B as a result of condensation between lysine residues and cyanate derived from urea. Carbamylated LDL is poorly recognized by LDL receptors and initiates different processes that can be considered proatherogenic. Thus, LDL carbamylation may contribute to the increase...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Arteriosclerosis, thrombosis, and vascular biology
دوره 25 12 شماره
صفحات -
تاریخ انتشار 2005